Compare FTS & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FTS | UTHR |
|---|---|---|
| Founded | 1885 | 1996 |
| Country | Canada | United States |
| Employees | 9900 | 1400 |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.2B | 23.9B |
| IPO Year | N/A | 1999 |
| Metric | FTS | UTHR |
|---|---|---|
| Price | $58.08 | $532.81 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 13 |
| Target Price | $72.00 | ★ $524.62 |
| AVG Volume (30 Days) | ★ 677.1K | 404.1K |
| Earning Date | 01-01-0001 | 05-28-2026 |
| Dividend Yield | ★ 3.16% | N/A |
| EPS Growth | N/A | ★ 13.07 |
| EPS | N/A | ★ 27.86 |
| Revenue | N/A | ★ $1,483,300,000.00 |
| Revenue This Year | $13.48 | $7.77 |
| Revenue Next Year | $6.05 | $11.11 |
| P/E Ratio | $22.72 | ★ $19.54 |
| Revenue Growth | N/A | ★ 2.38 |
| 52 Week Low | $43.28 | $266.98 |
| 52 Week High | $58.23 | $548.12 |
| Indicator | FTS | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 66.88 | 61.99 |
| Support Level | $50.65 | $463.64 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.87 | 19.18 |
| MACD | -0.07 | 5.07 |
| Stochastic Oscillator | 88.98 | 85.06 |
Fortis owns and operates eight utility transmission and distribution subsidiaries in Canada and the United States, serving roughly 3.5 million electricity and gas customers. The company has smaller stakes in electricity generation and several Caribbean utilities. Subsidiary ITC operates electric transmission in seven US states, with more than 16,000 miles of high-voltage transmission lines in operation.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.